Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Post by fouremmon Jun 10, 2013 3:47pm
289 Views
Post# 21507841

A few thoughts...

A few thoughts...

I agree with KayakerBC and Windymere that the drop in price is based in retail investor fear and if, as Windymere said, there was a "leak" that the drop would be much larger and the volume would be huge.  "Leaks", as most of us know, don't generally land in the ears of small players.  Additionally, the distribution of shares by brokerage would not, to me, indicate that someone knows something that isn't available to everyone else.

 

In addition to fear I think some investors may be adjusting their holdings from a risk reward standpoint depending on their view of what the future value may be of RVX.  I know from this board there were different interpretations of what value remains in RVX as far as future earnings potential in the event of a sale.

 

Regarding Institutional Investors, I doubt if they will participate in any buying to support the price.  Why do so prior to an ASSURE announcement when the price is going their way anyhow.  I would more expect that they would participate in the rally should good ASSURE results be released.

 

As far as the company making a statement regarding the fall in price, I doubt if management will make a statement on its' own accord but you never know.  When the share price was on the rise for no apparent reason, RVX was ordered to make a statement by the TSX.

 

Personally I think the odds are that ASSURE results will be good;  As others have said SUSTAIN top line results were good and anything else in that study which would have been materially negative would have had to be released; To my knowledge there was nothing negative published during ASSURE;  And, don't forget that when ASSURE was put on hold way back during ASSERT it was because RVX had a clearer view of who their patient population was and as such the recruitment criteria for ASSURE was refined.  That bodes well for the outcome. 

 

All of course IMO

 

 

Bullboard Posts